AIMS: To assess the vitreous penetration of oral levofloxacin (a new fluoroquinolone antibiotic with improved Gram positive activity) in uninflamed phakic eyes. METHODS: 15 patients for macula hole surgery were recruited to the study. 10 received a single 500 mg dose of levofloxacin by mouth preoperatively. Five acted as controls. Serum and undiluted vitreous samples were obtained at surgery and analysed by HPLC. RESULTS: Levofloxacin was detectable 2.5 hours after administration in the vitreous. A peak concentration of 1.6 microg/ml (or mg/l) was measured between 2.5 and 4 hours post-dose. CONCLUSION: Oral levofloxacin reaches the vitreous rapidly in the uninflamed phakic eye. Levels did not reach MIC(90) for the commonest infecting organisms. Nevertheless, levofloxacin would be expected to be active against a higher proportion of infecting organisms than either ciprofloxacin or ofloxacin.
AIMS: To assess the vitreous penetration of oral levofloxacin (a new fluoroquinolone antibiotic with improved Gram positive activity) in uninflamed phakic eyes. METHODS: 15 patients for macula hole surgery were recruited to the study. 10 received a single 500 mg dose of levofloxacin by mouth preoperatively. Five acted as controls. Serum and undiluted vitreous samples were obtained at surgery and analysed by HPLC. RESULTS:Levofloxacin was detectable 2.5 hours after administration in the vitreous. A peak concentration of 1.6 microg/ml (or mg/l) was measured between 2.5 and 4 hours post-dose. CONCLUSION: Oral levofloxacin reaches the vitreous rapidly in the uninflamed phakic eye. Levels did not reach MIC(90) for the commonest infecting organisms. Nevertheless, levofloxacin would be expected to be active against a higher proportion of infecting organisms than either ciprofloxacin or ofloxacin.
Authors: R G Fiscella; T K Nguyen; M J Cwik; B A Phillpotts; S M Friedlander; D C Alter; M J Shapiro; N P Blair; J P Gieser Journal: Ophthalmology Date: 1999-12 Impact factor: 12.079
Authors: G Keren; A Alhalel; E Bartov; R Kitzes-Cohen; E Rubinstein; S Segev; G Treister Journal: Invest Ophthalmol Vis Sci Date: 1991-07 Impact factor: 4.799
Authors: Asad F Durrani; Peter Y Zhao; Yunshu Zhou; Michael Huvard; Lyna Azzouz; Jason M Keil; Stephen T Armenti; Vaidehi S Dedania; David C Musch; David N Zacks Journal: Clin Ophthalmol Date: 2021-05-18